Tag - CytoAgents

Companies To Watch: CytoAgents

CytoAgents primarily focuses on developing a single lead drug, coded CTO1681, in multiple indications involving cytokine release syndrome (CRS). Simply stated, CRS is “an overreaction of the immune system, commonly known as cytokine storm.” It has many causes and affects many areas and systems of the body. CTO1681 targets the NF-kB (nuclear factor kappa B) signaling pathway to modulate cytokine production, thus reducing inflammation. CytoAgents has early programs in four areas: oncology (with CAR T-cell therapy), dermatology (atopic dermatitis), neurology...
Read more...

CytoAgents Announces Appointment of New Chief Medical Officer

CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer. Dr. Bertolino is a seasoned senior pharmaceuticals executive who has led clinical development and business growth for early-stage biotechnology as well as mid-sized and large pharmaceutical companies. Through extensive domestic and international management and drug development experience, including C-level roles...
Read more...

In Her Own Words: Covid propels Teresa Whalen to improve cancer treatment

As Omnicron continues to take a toll on the country, we’re reminded how many women are on the front lines of health care. Some in the hospital setting, some as public health leaders and others, like Teresa Whalen, in the research lab where, as CEO of CytoAgents, she leads a team of world-renowned clinical drug development experts and scientific advisory board members to find treatments for Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. Read...
Read more...

EY Announces 27 Women Founders Selected for the EY Entrepreneurial Winning Women™ North America Class of 2021

EY announces the 27 women founders selected for the EY Entrepreneurial Winning Women™ North America Class of 2021. The program, now in its 14th year, identifies ambitious women entrepreneurs who are leading thriving organizations and provides them with the access, advisors and resources needed to scale their companies to their full potential as market-leading innovators. Program engagement offers participants executive education and introductions to the vast EY global entrepreneurial ecosystem as well as the Entrepreneurial Winning Women community worldwide. Teresa...
Read more...

Wolf Administration Highlights Development of Promising New Drug Candidate to Treat COVID-19

On Wednesday, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation Works Chief Executive Officer Richard Lunak joined Teresa Whalen, CEO of Pittsburgh-based CytoAgents, to highlight the development of a new COVID-19 treatment. “This exciting new development was made possible by the strong partnerships the Wolf Administration has fostered with our Ben Franklin Technology Partners and the companies they support, like CytoAgents,” said D’Ettorre. Read more >>
Read more...

Pittsburgh-based company behind ‘promising’ new COVID-19 treatment

On Wednesday, the Wolf Administration plans to highlight what it calls in a news advisory a “promising new drug candidate to treat COVID-19.” The Department of Community and Economic Development will announce that Pittsburgh-based biotechnology company CytoAgents has begun its Phase 1 clinical trial for COVID-19 treatment. Read more >>
Read more...

How CytoAgents’ plans for growth run far beyond Covid crisis

GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said. Out clinical trials as well as plans for growth to include other uses for the dreuge. CytoAgents is working in Australia with its partner, Novotech, on the phase one clinical trial of GP1681...Read more >>
Read more...